Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700 · View on ClinicalTrials.gov ↗
Study Summary
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy: * Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy
Conditions Studied
Interventions
- BIOLOGICAL Sacituzumab tirumotecan
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Rescue Medication
Study Locations (20)
California
- Roy and Patricia Disney Family Cancer Center ( Site 0055) — Burbank
- Providence Medical Foundation ( Site 0080) — Fullerton
- Hoag Memorial Hospital Presbyterian ( Site 0010) — Newport Beach
- Helios Clinical Research ( Site 0061) — Whittier
Florida
- AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044) — Altamonte Springs
- Florida Cancer Specialists - South ( Site 7004) — Fort Myers
- Bioresearch Partner ( Site 0072) — Hialeah
- Florida Cancer Specialists - North ( Site 7002) — St. Petersburg
Arizona
- Banner MD Anderson Cancer Center ( Site 0066) — Gilbert
- University of Arizona Cancer Center ( Site 0035) — Tucson
Colorado
- Intermountain Health Cancer Center Saint Joseph ( Site 0062) — Denver
- Intermountain Health St. Mary's Regional Hospital ( Site 0054) — Grand Junction
Indiana
- Fort Wayne Medical Oncology and Hematology ( Site 0084) — Fort Wayne
- Franciscan Health ( Site 0077) — Indianapolis
Louisiana
- Ochsner Clinic Foundation ( Site 0021) — New Orleans
- Louisiana State University Health Sciences Shreveport ( Site 0053) — Shreveport
Missouri
- Saint Luke's Cancer Institute ( Site 0059) — Kansas City
- Washington University Siteman Cancer Center ( Site 0031) — St Louis
Maine
- New England Cancer Specialists ( Site 0051) — Westbrook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,400 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2034-12-29 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06966700
The ClinicalTrials.gov registry entry for NCT06966700 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 741 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions — of which Sacituzumab tirumotecan is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06966700 reports 20 study locations spanning 9 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06966700 about?
NCT06966700 is a clinical study titled "A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)". Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of...
What is the current status of trial NCT06966700?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,400 participants. The study started on 2025-06-30. Estimated completion is 2034-12-29.
What conditions does trial NCT06966700 study?
This clinical trial studies the following conditions: Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06966700?
The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Paclitaxel (DRUG), Rescue Medication (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06966700?
This trial is sponsored by Merck Sharp & Dohme, which has 741 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06966700 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.